search button
Open Access

Prognostic factor analysis and clinical significance of HER‑2‑positive breast cancers with negative lymph nodes and a tumor diameter ≤1 cm

  • Authors:
    • Shanshan Yan
    • Yongnan Wang
    • Yujuan Guo
    • Yan Zhang
    • Haiyan Peng
    • Huang Tang
    • Yizhong Luo
    • Anqin Zhang
    • Hongyi Gao

  • View Affiliations

  • Published online on: September 28, 2023     https://doi.org/10.3892/ol.2023.14078
  • Article Number: 491

  • Copyright: © Yan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The 2021 National Comprehensive Cancer Network guidelines recommend that adjuvant chemotherapy combined with trastuzumab be considered for human epidermal growth factor receptor 2 (HER‑2)‑positive breast cancer patients with small tumors (tumor diameter ≤1 cm) and negative lymph nodes. Additionally, the prognostic factors and clinical significance of HER‑2‑positive breast cancer with negative lymph nodes and a tumor diameter ≤1 cm remain unclear. In the present study, the clinical data and prognostic factors of 87 patients with HER‑2‑positive breast cancer with negative lymph nodes and a tumor diameter ≤1 cm admitted to Guangdong Women and Children Hospital from January 2013 to December 2019 were retrospectively analyzed. The median follow‑up time was 70 months, the disease‑free survival (DFS) of all patients was 94.3% and the overall survival (OS) was 100%. Univariate analysis of prognosis demonstrated that patients aged ≤40 years had significantly lower DFS than those aged >40 (80.8 vs. 100.0%, P<0.001). DFS was significantly improved in patients who were hormone‑receptor‑positive and patients who received endocrine therapy compared with patients who were estrogen receptor negative and patients who did not receive endocrine therapy (100.0 vs. 89.6%, P=0.039; 100.0 vs. 90.0%, P=0.049). Prognostic univariate analysis demonstrated that patient age, hormone receptor status and use of endocrine therapy were significantly related to the DFS (P<0.05), while none of these were independent factors related to the DFS in the prognostic multivariate analysis (P=0.240, P=0.976 and P=0.925). The proportion of patients with a tumor diameter 0.5‑1 cm receiving adjuvant anti‑HER‑2 treatment was significantly greater compared with patients with tumors with a diameter ≤0.5 cm (46.4 vs. 18.6%, P<0.05). There was no significance difference in the DFS of patients treated with adjuvant chemotherapy with or without anti‑HER‑2 therapy with tumor diameters ≤0.5 cm (P>0.05), but there was a significant difference in the DFS of patients with a tumor diameter 0.5‑1 cm (P<0.05). These results suggested that adjuvant chemotherapy, with or without anti‑HER‑2 therapy, may affect the prognosis of HER‑2‑positive breast cancer patients with negative lymph nodes and a tumor diameter of 0.5‑1 cm. Therefore, it could be recommended that such patients receive adjuvant chemotherapy and anti‑HER‑2 therapy in the future.
View Figures
View References

Related Articles

Journal Cover

November-2023
Volume 26 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.5
  • Ranked Oncology
    (total number of cites)
  • CiteScore: 5.7
  • CiteScore Rank: Q2: #139/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.574
  • SCImago Journal Rank (SJR): 0.644
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Yan S, Wang Y, Guo Y, Zhang Y, Peng H, Tang H, Luo Y, Zhang A and Gao H: Prognostic factor analysis and clinical significance of HER‑2‑positive breast cancers with negative lymph nodes and a tumor diameter ≤1 cm. Oncol Lett 26: 491, 2023
APA
Yan, S., Wang, Y., Guo, Y., Zhang, Y., Peng, H., Tang, H. ... Gao, H. (2023). Prognostic factor analysis and clinical significance of HER‑2‑positive breast cancers with negative lymph nodes and a tumor diameter ≤1 cm. Oncology Letters, 26, 491. https://doi.org/10.3892/ol.2023.14078
MLA
Yan, S., Wang, Y., Guo, Y., Zhang, Y., Peng, H., Tang, H., Luo, Y., Zhang, A., Gao, H."Prognostic factor analysis and clinical significance of HER‑2‑positive breast cancers with negative lymph nodes and a tumor diameter ≤1 cm". Oncology Letters 26.5 (2023): 491.
Chicago
Yan, S., Wang, Y., Guo, Y., Zhang, Y., Peng, H., Tang, H., Luo, Y., Zhang, A., Gao, H."Prognostic factor analysis and clinical significance of HER‑2‑positive breast cancers with negative lymph nodes and a tumor diameter ≤1 cm". Oncology Letters 26, no. 5 (2023): 491. https://doi.org/10.3892/ol.2023.14078